Roivant和Immunovant Say IMVT-1402（Imeroprubart）治疗皮肤狼疮红斑狼疮概念验证试验第1阶段的总体结果在主要终点上没有达到统计学意义

2026-09-23 19:05

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12
Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLE
IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies
All other clinical development timelines remain on track